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stuBACKGROUND Aspiration thrombectomy in ST-segment elevation myocardial infarction is recommended by current
guidelines based on several randomized trials. There are no trials assessing thrombectomy in non–ST-segment elevation
myocardial infarction (NSTEMI) patients.
OBJECTIVES The TATORT-NSTEMI (Thrombus Aspiration in Thrombus Containing Culprit Lesions in Non–ST-Elevation
Myocardial Infarction) trial sought to assess the effect of aspiration thrombectomy on microvascular injury in patients
with NSTEMI compared with standard percutaneous coronary intervention (PCI).
METHODS This prospective, controlled, multicenter study randomized 440 patients to adjunctive thrombectomy
(n ¼ 221) compared with conventional PCI (n ¼ 219) in NSTEMI patients with thrombus-containing lesions. The primary
endpoint of the extent of microvascular obstruction (MO) in the percentage of left ventricular mass (%LV) was assessed
by cardiac magnetic resonance imaging within 4 days. Secondary endpoints included infarct size, myocardial salvage
index, and angiographic parameters including myocardial blush grade and Thrombolysis In Myocardial Infarction ﬂow
grade. The combined clinical endpoint consisted of death, reinfarction, target vessel revascularization, and new
congestive heart failure within 6 months.
RESULTS The primary endpoint of MO was not different between the thrombectomy and the standard PCI group with
2.0%LV (interquartile range [IQR]: 0.8 to 4.1) versus 1.4%LV (IQR: 0.7 to 2.6) (p ¼ 0.17). Similarly, no signiﬁcant dif-
ferences were observed for infarct size (8.6%LV; IQR: 4.0 to 14.7 vs. 7.4%LV; IQR: 4.1 to 13.1; p ¼ 0.46), myocardial
salvage index (63.3; IQR: 35.4 to 87.2 vs. 65.6; IQR: 46.9 to 82.6; p ¼ 0.45), or angiographic parameters such as blush
grade (p ¼ 0.63) and Thrombolysis In Myocardial Infarction ﬂow grade (p ¼ 0.66). Clinical follow-up at 6 months
revealed no differences in the combined clinical endpoints (p ¼ 0.22).
CONCLUSIONS Aspiration thrombectomy in conjunction with PCI in NSTEMI with a thrombus-containing lesion does
not lead to a reduction in MO. (Thrombus Aspiration in Thrombus Containing Culprit Lesions in Non-ST-Elevation
Myocardial Infarction [TATORT-NSTEMI]; NCT01612312) (J Am Coll Cardiol 2014;64:1117–24) © 2014 by the American
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obstruction
NSTEMI = non–ST-segment
elevation myocardial infarction
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
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1118T he use of manual thrombectomyduring percutaneous coronary inter-vention (PCI) in patients with acute
ST-segment elevation myocardial infarction
(STEMI) has been shown to improve perfu-
sion and in meta-analyses also to decrease
cardiac death and repeat myocardial infarc-
tion (1–3). Consequently, current European
and U.S. guidelines recommend manual
thrombectomy in patients with STEMI (4,5).
However, in non–ST-segment elevation
myocardial infarction (NSTEMI), w50% to
70% of all patients also display relevant
thrombus burden in the culprit vessel (6–8).
Furthermore, with rates of angiographic no-
reﬂow ranging from 15% to 40% depending
on thrombus burden and intraprocedural
thrombotic events, in a signiﬁcant portion ofpatients with NSTEMI, only suboptimal reperfusion
success can be achieved (9–11). Thus, thrombectomy
in patients with NSTEMI may represent a useful
intervention with the potential to reduce myocardial
damage and improve patient prognosis. Due to a
lack of data, current guidelines do not give a
clear recommendation for thrombus aspiration in
NSTEMI (12).SEE PAGE 1125The lack of guideline recommendations underlines
the need for an adequately powered randomized
clinical trial to address the current role of thrombus
aspiration in patients with NSTEMI and relevant
thrombus. The TATORT-NSTEMI (Thrombus Aspira-
tion in Thrombus Containing Culprit Lesions in
Non-ST-Elevation Myocardial Infarction) trial was
designed to test the hypothesis that adjunctive
thrombectomy compared with conventional PCI
alone leads to a reduction in microvascular obstruc-
tion (MO) assessed by cardiac magnetic resonance
(CMR) imaging.
METHODS
TATORT-NSTEMI is a prospective, controlled, multi-
center, randomized, open-label trial designed to
compare PCI with routine thrombus aspiration with PCI
without thrombus aspiration in NSTEMI patients andy design, data collection, data analysis, and ﬁnal drafting of this
erumo. Dr. Zeymer has received consulting and research grants f
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received March 3, 2014; revised manuscript received May 4, 201relevant thrombus burden undergoing early invasive
PCI. The detailed methods and design of this trial were
published previously (13). In brief, inclusion criteria
were the following: 1) ischemic symptoms lasting >20
min; 2) occurrence of last symptoms <72 h before
randomization; 3) cardiac troponin T levels above the
99th percentile; 4) culprit lesion containing thrombus
(Thrombolysis InMyocardial Infarction [TIMI] thrombus
grades 2 to 5within the lesion); and5) intendedearly PCI.
Exclusion criteria were cardiogenic shock, STEMI, no
identiﬁable culprit lesion, coronary morphology ineli-
gible for thrombectomy (e.g., very tortuous vessels, se-
vere calciﬁcation); indication for acute bypass surgery;
age younger than 18 and older than 90 years; contrain-
dications to treatment with heparin, aspirin, or thieno-
pyridines; pregnancy; current participation in another
clinical study; comorbidity with a limited life
expectancy<6months; and contraindications to CMR at
study entry. All patients gave written informed consent
before randomization. The lead ethical committee at the
University of Leipzig and at all local ethical committees
of the participating sites approved the study.
PRIMARY AND SECONDARY ENDPOINTS. The pri-
mary study endpoint of the TATORT-NSTEMI trial
was deﬁned as the extent of late MO assessed by CMR
at days 1 to 4 after randomization. Secondary end-
points included other CMR parameters of myocardial
damage, such as infarct size, myocardial salvage (14),
myocardial salvage index, and left ventricular (LV)
ejection fraction. Furthermore, angiographic markers
of reperfusion success such as the TIMI ﬂow post-PCI
and myocardial blush grade were assessed.
For enzymatic infarct size determination, high-
sensitivity troponin T after 24 and 48 h was
evaluated. A combined clinical endpoint of death,
reinfarction, target vessel revascularization, and new
congestive heart failure was assessed within 6
months of follow-up. The detailed deﬁnitions for the
individual endpoints were published previously and
reﬂect standard deﬁnitions (13,15). Clinical outcome
at follow-up was assessed by a telephone interview.
Any clinical event was veriﬁed by hospital or general
practitioner records. All clinical and safety endpoints
were adjudicated based on data provided by the
clinical trial sites by a Clinical Endpoints Committee
blinded to treatment assignment.manuscript. Dr. Thiele has received grants from Eli
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460 NSTEMI patients with thrombus
Not randomized (n=20)
440 NSTEMI patients
221 assigned to thrombectomy
No CMR (n=40)
Primary endpoint analysis MO (n=181)
Secondary endpoint MBG (n=184)
Secondary endpoint TIMI-flow (n=221)
Clinical follow-up 6 months (n=220)
Primary endpoint analysis MO (n=192)
Secondary endpoint MBG (n=179)
Secondary endpoint TIMI-flow (n=219)
Clinical follow-up 6 months (n=218)
No CMR (n=27)
Claustrophobia (n=11) Claustrophobia (n=5)
PM/ICD (n=2)
Obesity (n=1)
Death (n=3)
Other (n=23)
PM/ICD (n=3)
Obesity (n=1)
Death (n=3)
Other (n=14)
Renal insuff. (n=1)
219 assigned to standard PCI
FIGURE 1 Study Flow Chart
Study ﬂow chart indicating the number of randomized patients and patients with endpoint
assessment. CMR ¼ cardiac magnetic resonance; insuff. ¼ insufﬁciency; MBG ¼ myocardial
blush grade; MO ¼ microvascular obstruction; NSTEMI ¼ non–ST-segment elevation
myocardial infarction; PCI ¼ percutaneous coronary intervention; PM/ICD ¼ pacemaker/
implantable cardioverter-deﬁbrillator; TIMI ¼ Thrombolysis In Myocardial Infarction.
FIGURE 2 Patient With MO After Thrombotic Occlusion of the Left Circumﬂex Artery
(A) Contrast-enhanced image showing transmural inferolateral necrosis with a core of late
microvascular obstruction (MO). (B) Contours for assessment of infarct size and the extent
of MO (red contour, endocardial; green, epicardial; dark blue, remote myocardium; pink,
infarcted myocardium; light blue, MO). (C) Computer-aided signal intensity analysis of
infarct size and MO normalized to normal, uninjured myocardium. The yellow overlay
(infarct size) indicates a signal intensity of >5 SDs above remote, uninjured myocardium.
The orange overlay within the infarct indicates the computer-detected area of MO.
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1119Safety assessment included stroke and bleeding
until hospital discharge. Bleeding severity was
classiﬁed according to the GUSTO (Global Use of
Strategies to Open Occluded Coronary Arteries)
criteria as severe or life-threatening, moderate, or
mild bleeding.
CMR IMAGE ACQUISITION AND ANALYSIS. The pri-
mary endpoint of late MO and other secondary
endpoints, such as infarct size and myocardial
salvage, were assessed by CMR performed on a 1.5- or
3.0-T scanner on days 1 to 4 after randomization
using a standard scan protocol, as described previ-
ously (13). In brief, late MO and infarct size were
assessed using delayed-enhancement short-axis im-
ages covering the whole left ventricle w15 min after
injection of gadolinium chelate. An inversion recov-
ery turbo gradient echo sequence was used for
image acquisition. For determination of edema/area
at risk, short-axis slices covering the whole left
ventricle using a T2-weighted imaging triple in-
version recovery turbo spin echo sequence before
contrast administration were obtained. The myo-
cardial salvage index was calculated as edema (area
at risk) minus infarct size divided by the area at risk,
as described previously (14). Assessment of LV func-
tion and volumes was performed by a standard
steady-state free precession technique acquiring
short-axis slices from base to apex. LV ejection frac-
tion was calculated from the short-axis functional
views. The scan protocol and core laboratory image
analysis were standardized at all sites and have been
used effectively in previous multicenter studies
(16–19). The blinded observers used certiﬁed CMR
evaluation software (cmr42, Circle Cardiovascular Im-
aging Inc., Calgary, Alberta, Canada). Semiautomated
computer-aided threshold detection was applied to
identify regions of edema, hypointense cores, MO,
and infarcted myocardium, as previously described
(8–10). Infarct size, area at risk, and MO were ex-
pressed as the percentage of LV mass (%LV). The CMR
core laboratory has excellent reproducibility and
low interobserver and intraobserver variability for
infarct size and myocardial salvage assessment (12).
ASSESSMENT OF SECONDARY ANGIOGRAPHIC
ENDPOINTS. A central blinded analysis for TIMI
ﬂow, blush grade, and thrombus burden was per-
formed at the angiographic core laboratory of the
University of Saarland. Evaluation of thrombus
burden was performed according to the TIMI
thrombus grade scale.
STATISTICAL ANALYSIS. The aim of this study was
to demonstrate superiority of manual thrombus
aspiration compared with standard PCI with respectto the primary endpoint of late MO. Initially, the
sample size calculation estimated an absolute dif-
ference in the primary endpoint of late MO of 1.0 
3.3%LV between the 2 treatment groups (20). Based
on a ¼ 5%, a 2-sided hypothesis test, and a statis-
tical power of 80%, 172 patients per group were
needed. During the course of the trial, 2 other studies
were published on MO and NSTEMI, reporting a lower
prevalence and extent of MO than expected (21,22).
Therefore, the Steering Committee decided to increase
the sample size to 204 patients per group, assuming
TABLE 1 Patient and Procedural Characteristics
Thrombectomy
(n ¼ 221)
Standard PCI
(n ¼ 219) p Value
Age, yrs 69 (58–75) 68 (58–74) 0.60
Male 158 (72) 163 (74) 0.54
Cardiovascular risk factors
Current smoking 92 (42) 80 (37) 0.26
Hypertension 180 (81) 166 (65) 0.12
Hypercholesterolemia 81 (37) 85 (39) 0.67
Diabetes mellitus 64 (29) 64 (29) 0.98
BMI, kg/m2 28 (25–31) 28 (25–31) 0.55
Previous infarction 16 (7) 26 (12) 0.10
Previous PCI 12 (6) 29 (13) <0.01
Previous CABG 7 (3) 10 (5) 0.45
Systolic blood pressure, mm Hg 144 (125–160) 140 (121–158) 0.32
Heart rate, beats/min 76 (68–86) 76 (67–85) 0.78
GRACE score 145 (116–168) 137 (115–162) 0.27
Radial arterial access 30 (14) 29 (13) 0.90
Killip class on admission 0.88
1 196 (88) 194 (89)
2 22 (10) 22 (10)
3 3 (1) 3 (1)
4 1 (1) 0
Diseased vessels 0.21
1 87 (39) 105 (48)
2 84 (39) 64 (29)
3 50 (22) 50 (23)
Infarct-related artery 0.56
Left anterior descending 78 (35) 73 (33)
Left circumﬂex 87 (39) 90 (41)
Right coronary 50 (23) 51 (23)
Left main 1 (1) 0
Bypass graft 5 (2) 5 (2)
Thrombectomy performed 217 (98) 0 <0.001
Aspiration of macroscopic
thrombus material
162 (73) –
Primary stenting 131 (59) 96 (44) <0.01
Drug-eluting stent 154 (75) 153 (70) 0.56
Bare-metal stent 65 (29) 66 (30) 0.89
Concomitant medications
Bivalirudin 5 (2) 5 (2) 0.99
Unfractionated heparin 199 (90) 198 (90) 0.98
LMW heparin 17 (8) 16 (7) 0.87
Beta-blockers 207 (94) 207 (95) 0.66
ACE inhibitors/AT-1
antagonist
185 (84) 187 (86) 0.61
Aspirin 219 (99) 217 (99) 0.62
Clopidogrel 57 (26) 57 (26) 0.95
Prasugrel 92 (41) 83 (38) 0.61
Ticagrelor 72 (33) 79 (33) 0.66
Glycoprotein IIb/IIIa inhibitors 13 (6) 14 (6) 0.83
Statins 212 (96) 211 (97) 0.77
Aldosterone antagonist 45 (20) 32 (15) 0.11
Values are median (interquartile range) or n (%).
ACE ¼ angiotensin-converting enzyme; AT-1 ¼ angiotensin 1; BMI ¼ body mass index; CABG ¼ coronary artery
bypass graft; GRACE ¼ Global Registry for Acute Coronary Events; LMW ¼ low molecular weight; PCI ¼ primary
percutaneous coronary intervention.
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1120an absolute difference in MO of 0.5  1.8%LV between
the 2 treatment groups with a mean extent of 1.0%LV
of late MO in the whole study cohort. This difference
was judged clinically relevant (20). On the basis of
clinical experience and data on STEMI, it was further
expected that thrombectomy could not be performed
in 5% of all patients in the thrombectomy group and
that as many as 10% of all patients would have no
CMR data (19,20). This resulted in a total sample size of
2  230 patients.
Pre-speciﬁed subgroup analyses by sex, the pres-
ence of diabetes, TIMI thrombus burden (2 to 4 vs. 5),
TIMI ﬂow pre-PCI (0 to 1 vs. 2 to 3), and additional
administration of glycoprotein IIb/IIIa inhibitors
were performed. Interactions between treatment
groups were tested by a general linear model. The
pre-speciﬁed subgroup analysis based on symptom
duration could not be performed due to a large
number of missing variables as symptom onset could
not be clearly determined in w50% of patients.
A multivariable logistic regression analysis was
performed to assess predictors of MO. The variables
included were sex, previous infarction, smoking, hy-
pertension, hypercholesterolemia, diabetes, culprit
lesion location, number of diseased vessels, and TIMI
ﬂow and TIMI thrombus grade before PCI.
All data were analyzed according to the intention-
to-treat principle. The differences in primary and
secondary endpoints between treatment groups were
assessed for continuous numerical variables by the
Wilcoxon rank sum test. Categorical variables were
analyzed by the chi-square or Fisher exact test. For
clinical events, the hazard ratio and 95% conﬁdence
interval are reported as well as Kaplan-Meier curves
with log-rank comparison. A 2-tailed p value <0.05
was considered statistically signiﬁcant.
RESULTS
Of the 460 patients initially scheduled for randomi-
zation, only 440 patients were ultimately enrolled.
Due to a technical error in the Internet-based ran-
domization system, 20 data slots were erroneously
marked as randomized patients. This was only
discovered at the ﬁnal database lock and analysis.
Given the unambiguous study results, the Steering
Committee decided to close the study at 440 patients
and not to randomize another 20 patients. Thus, 221
were randomly assigned to thrombectomy and 219 to
standard PCI (Figure 1).
All patients received the assigned treatment, and
thrombectomy was successfully performed in 217
patients (98%) in the thrombectomy group with
macroscopic thrombus aspiration in 73%. There was
TABLE 2 Cardiac Magnetic Resonance Imaging Results
Thrombectomy
(n ¼ 181)
Standard PCI
(n ¼ 192) p Value
Area at risk (edema), %LV 21.0 (16.6–25.8) 20.3 (14.9–25.0) 0.11
Infarct size, %LV 8.6 (4.0–14.7) 7.4 (4.1–13.1) 0.42
Myocardial salvage, %LV 11.2 (7.0–16.9) 11.9 (7.4–17.2) 0.78
Myocardial salvage index 63.3 (35.4–87.2) 65.6 (46.9–82.6) 0.45
MO present 58 (32.0) 58 (30.2) 0.79
MO, %LV 1.9 (0.8–4.1) 1.4 (0.7–2.6) 0.17
LV ejection fraction, % 50 (44–56) 52 (44–59) 0.10
LV end-diastolic volume, ml 140 (112–165) 136 (115–168) 0.80
LV end-systolic volume, ml 66 (52–90) 65 (51–86) 0.42
Values are median (interquartile range) or n (%).
LV ¼ left ventricular; %LV ¼ percentage of left ventricular mass; MO ¼ microvascular
obstruction; PCI ¼ percutaneous coronary intervention.
Baseline variable
All Patients 373
0.97
0.73
0.74
0.82
0.25
0.23
-3 -2 -1 0 1 2 3
273
100
99
274
246
127
199
174
24
349
166
207
No. patients
Standard PCI
better
Thrombectomy
better
p Value 
for interaction
Mean difference in MO %LV
(95% confidence interval)
Male sex
Female sex
Diabetes
No diabetes
TIMI thrombus grade 2-4
TIMI thrombus grade 5
TIMI-flow pre PCI 0-1
TIMI-flow pre PCI 2-3
Glycoprotein IIb/IIIa-inhibitor
No glycoprotein IIb/IIIa-inhibitor
Direct stenting
No direct stenting
FIGURE 3 Primary Endpoint MO and Subgroups
Mean difference and 95% conﬁdence intervals in the primary endpoint of MO in the %LV
between the standard PCI group and the thrombectomy group for predeﬁned and post-hoc
subgroups. %LV ¼ percentage of left ventricular mass; PCI ¼ percutaneous coronary
intervention; other abbreviations as in Figure 1.
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1121no crossover in the standard PCI group. The baseline
characteristics and medication were similar between
groups with the exception of a higher rate of previous
PCIs in the standard PCI group (Table 1). Procedural
characteristics and in-hospital medication also were
similar between groups. However, in the thrombec-
tomy group, signiﬁcantly more patients underwent
primary stenting without pre-dilation of the lesion
(p < 0.001) (Table 1).
CMR IMAGING. Results of CMR imaging were avail-
able in 181 (82%) of the thrombectomy group and
in 192 (88%) of the standard PCI group (Figure 1).
Reasons for not undergoing CMR are listed in Figure 1.
The median time between randomization and CMR
was 1 day (interquartile range [IQR]: 1 to 3 days) in the
thrombectomy group and 1 day (IQR: 1 to 2 days) in
the standard PCI group (p ¼ 0.49). Figure 2 shows a
typical ﬁnding on CMR imaging in a patient with a
lateral infarction with MO. There was no difference in
the primary endpoint of late MO or in any other
parameter derived from CMR imaging (Table 2).
There was also no effect of thrombectomy in the pre-
deﬁned subgroups (Figure 3). Multivariable predictors
of MO presence were pre-PCI TIMI ﬂow, diabetes, and
culprit lesion location in the left anterior descending
and left circumﬂex arteries.
ANGIOGRAPHIC ENDPOINTS. Angiographic central
assessment of the TIMI ﬂow grades was possible in
all patients, whereas the blush grade was only
assessable in 83% of the patients due to technical
reasons and/or image quality (Figure 1). There were
no differences in angiographic parameters at base-
line as well as after PCI in the 2 randomized groups
(Table 3).
ENZYMATIC INFARCT SIZE. The enzymatic infarct
size assessed by high-sensitivity troponin T values
was similar in the thrombectomy group and the
standard PCI group with 960 ng/l (IQR: 295 to
2,077 ng/l) versus 739 ng/l (IQR: 360 to 1,549 ng/l) at
24 h (p ¼ 0.24) and also at 48 h (1,038 ng/l [IQR: 362 to
2,010 ng/l] vs. 885 ng/l [IQR: 337 to 1,562 ng/l];
p ¼ 0.20).
CLINICAL OUTCOME. At 6 months of follow-up,
there were 6 deaths (2.8%) in the thrombectomy
group versus 10 deaths (4.6%) in the standard PCI
group (p ¼ 0.30). Nonfatal reinfarctions occurred in 4
(1.9%) after thrombectomy and in 5 (2.4%) in the
standard PCI group (p ¼ 0.72); target vessel revascu-
larization was observed in 2.8% versus 1.9%
(p ¼ 0.54). New congestive heart failure was regis-
tered in 4 patients (1.8%) in the thrombectomy group
and 9 patients (4.2%) in the standard PCI group(p ¼ 0.16). Thus, the composite major adverse cardiac
event rate at 6 months of follow-up was 7.3% after
thrombectomy and 10.6% in the standard PCI group
(hazard ratio: 0.68; 95% conﬁdence interval: 0.36 to
1.28; p ¼ 0.22), as shown in Figure 4.
Safety events were rare and not signiﬁcantly
different between both study groups. There were no
in-hospital strokes or severe/life-threatening bleed-
ings. Moderate bleeding occurred in 4 patients (2%) in
each group (p ¼ 0.99).
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FIGURE 4 Secondary Combined Clinical Endpoint
Kaplan-Meier curve of the combined clinical endpoint of death, reinfarction, target vessel
revascularization (TVR), and new congestive heart failure at 6-month follow-up. PCI ¼
percutaneous coronary intervention.
TABLE 3 Angiographic Results
Thrombectomy
(n ¼ 221)
Standard PCI
(n ¼ 219) p Value
TIMI thrombus grade
before PCI
0.91
2 29/221 (13) 21/219 (10)
3 59/221 (27) 66/219 (30)
4 57/221 (26) 61/219 (28)
5 76/221 (34) 71/219 (32)
TIMI ﬂow before PCI 0.61
0 86/221 (39) 81/219 (37)
I 20/221 (9) 13/219 (6)
II 58/221 (26) 70/219 (32)
III 57/221 (26) 55/219 (25)
TIMI ﬂow post-PCI 0.66
0 4/221 (2) 9/219 (4)
I 1/221 (1) 4/219 (2)
II 19/221 (9) 13/219 (6)
III 197/221 (89) 193/219 (88)
Myocardial blush grade
before PCI
0.92
0 80/184 (44) 72/179 (40)
I 47/184 (26) 56/179 (31)
II 54/184 (29) 50/179 (28)
III 3/184 (2) 1/179 (1)
Myocardial blush grade
post-PCI
0.63
0 4/181 (2) 4/179 (2)
I 8/181 (4) 7/179 (4)
II 49/181 (27) 55/179 (31)
III 120/181 (66) 113/179 (63)
Values are n/N (%).
PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial
Infarction.
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1122DISCUSSION
The main results of this ﬁrst randomized multicenter
trial assessing aspiration thrombectomy in patients
with NSTEMI with thrombus-containing lesions in
the infarct-related artery can be summarized as fol-
lows. Aspiration thrombectomy led to aspiration of
macroscopic thrombus material in 75% of patients,
which resulted in a signiﬁcantly higher rate of pri-
mary stent implantation without pre-dilation in the
thrombectomy group compared with the standard
PCI arm. However, aspiration thrombectomy did
not reduce the extent of MO compared with standard
PCI without thrombectomy, which is corroborated
by a lack of beneﬁt in secondary endpoints.
In patients with STEMI, the pivotal TAPAS
(Thrombus Aspiration During Percutaneous Coronary
Intervention in Acute Myocardial Infarction Study)
trial comparing a strategy of routine aspiration
thrombectomy with a strategy without thrombectomy
resulted in improved reperfusion indexes as the pri-
mary endpoint (2). Although not powered for clinical
outcome, cardiac mortality at 1 year also was reduced
(3). In contrast, in 1 recent randomized, controlled trial
involving high-risk anterior STEMI patients, throm-
bectomy in addition to standard PCI did not result in a
reduction of infarct size (23). Several meta-analyses in
STEMI patients demonstrated a mortality beneﬁt after
thrombectomy compared with standard PCI alone
(1,24–27). However, it also has been shown that singleormulticenter study design had a signiﬁcant impact on
outcomes in these trials, and the major effect was
driven by the single-center TAPAS trial. Nevertheless,
based on these data, current American and European
guidelines suggest performing manual aspiration
thrombectomy in STEMI with a Class IIa Level of Evi-
dence: B recommendation (4,5). These guideline rec-
ommendationswere recently challenged by the largest
randomized trial so far, which did not show amortality
beneﬁt with routine aspiration thrombectomy (28).
Another large-scale trial assessing the effects of
routine thrombus aspiration on clinically important
endpoints is currently ongoing (29).
In the majority of both STEMI and NSTEMI patients,
the key pathophysiological substrate is rupture of a
vulnerable plaque with subsequent coronary throm-
bosis (Central Illustration). Whereas in STEMI, the
thrombus is mostly ﬁbrin rich leading to total vessel
occlusion, the thrombus in many patients with
NSTEMI is predominantly platelet rich and unstable,
leading to only partial or intermittent occlusion of the
CENTRAL ILLUSTRATION Theoretical Advantage of Thrombectomy in NSTEMI
Illustration of the theoretical pathophysiological advantage of thrombectomy before
percutaneous coronary intervention (PCI) in non–ST-segment elevation
myocardial infarction (NSTEMI). Thrombectomy may reduce the thrombus burden and
prevent distal embolization with subsequent reduction of reperfusion injury
(i.e., microvascular obstruction), if applied before PCI. This was the hypothesis of the
TATORT-NSTEMI trial.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Thrombus is
frequently identiﬁed in the infarct-related artery in patients with
NSTEMI undergoing coronary angiography.
TRANSLATIONAL OUTLOOK: Larger trials powered for clin-
ical endpoints are needed to assess the impact of thrombectomy
on clinical outcomes in patients with NSTEMI.
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1123coronary vessel (12). Despite these pathophysiological
considerations, the majority of patients with NSTEMI
demonstrate relevant thrombus burden or even
occluded coronary arteries and thus might beneﬁt
from thrombectomy (6,8,11). Nevertheless, current
guidelines do not recommend thrombus aspiration in
NSTEMI patients (12,30). This is mainly due to the lack
of data in NSTEMI patients with only 1 published
prospective observational study so far (7). In this
observational study that included 70 NSTEMI pa-
tients, thrombus was detected in w50% on the initial
angiogram. Manual thrombus aspiration was associ-
ated with a signiﬁcant reduction of the TIMI thrombus
score and an increase in the rate of TIMI ﬂow grade 3.
After thrombus aspiration, direct stenting without
pre-dilation was possible in 56% of patients (7), which
is slightly lower than in our trial. Trials in STEMI pa-
tients also show heterogeneous direct stenting rates
ranging from 21% to 92% (26).
STUDY LIMITATIONS. A negative trial always raises a
question of power. Our initial sample size calculation
was mainly based on assumptions due to a lack of data
on NSTEMI. Based on new data published during the
course of the trial, the sample size was increased.
However, 20 patients, in principle eligible for the trial,
did not undergo ﬁnal randomization due to a technical
error. Thus, it may be argued that this trial is under-
powered. However, as there was numerically an even
greater extent of MO in the thrombectomy armwith no
effect in the secondary CMR, angiographic, and enzy-
matic endpoints, any beneﬁt of thrombectomy is
highly questionable. There was a slightly higher rate of
left circumﬂex artery lesions, and this may have
resulted in smaller infarcts than in other coronary ar-
teries. However, thrombus-containing lesions are
more often observed inferolaterally or poster-
olaterally, and this increases the infarct size and af-
fects clinical outcome (6). MO is a surrogate endpoint,
and evidently assessing clinical outcome as a primary
endpoint would lead to more robust data. However,
late MO has been shown to be a strong independent
predictor of clinical outcome (20). Blinding was not
possible as a result of the intervention used. Never-
theless, several methods to avoid bias were imple-
mented, such as blinded CMR imaging and
angiographic core laboratories, reducing any inﬂuence
of the open-label design of the trial. In clinical trials
using CMR parameters as surrogate endpoints, the
time period of CMR image acquisition after the index
event/randomization is of importance for the ﬁnal
quality and reproducibility of the results. Therefore, a
narrow time period of 1 to 4 days after randomization
was deﬁned, and there were no signiﬁcant differences
in the timing of CMR between the treatment groups.CONCLUSIONS
Manual aspiration thrombectomy in patients with
thrombus-containing lesions did not reduce the
extent of no-reﬂow compared with standard PCI as
measured by MO. These ﬁndings are supported by a
lack of beneﬁt in angiographic, enzymatic, and clin-
ical secondary endpoints.
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